

**PERIODICAL ASSESSMENT OF PATIENT RELATED  
FACTORS AND SETUP ERRORS THAT AID IN  
REPLANNING IN HEAD AND NECK CANCERS**

**A PROSPECTIVE STUDY**



A dissertation submitted to The Tamilnadu Dr. M.G.R. Medical University,  
Chennai In partial fulfillment of the requirements for the award .The degree of  
**DOCTOR OF MEDICINE (M.D.) IN RADIOTHERAPY** April 2016

## CERTIFICATE

This is to certify that this dissertation titled, **“PERIODICAL ASSESSMENT OF PATIENT RELATED FACTORS AND SETUP ERRORS THAT AID IN REPLANNING IN HEAD AND NECK CANCERS: A PROSPECTIVE STUDY.”** is a bonafide record of the work done by Dr.Priyadharsini.D.K, in the Division of Radiation Oncology, Cancer Institute (W. I. A.), Chennai, during the period of his postgraduate study for the degree of M.D. (Branch IX – Radiotherapy) from 2014-2015 under my direct guidance and supervision.

Date:

Dr.G.Selvaluxmy,

Place: Chennai

Professor and Head of Department,  
Division of radiation oncology,  
Cancer institute, (WIA), Chennai

## **ACKNOWLEDGMENT**

I would like to acknowledge my gratitude to late Dr.S.Krishnamurthy, advisor and Dr.V.Shantha, Executive chairman, Cancer institute(WIA) for providing me the opportunity to carry out this study.

I am grateful to Prof.Dr. Selvaluxmy, Professor , Head of the department of radiation oncology, Additional director, Cancer Institute for her continued encouragement and invaluable suggestions during this study. Without her this study would not have been possible. I also thank Dr.Vasanthan, Chairman of Division of Radiation oncology, Director Cancer Institute (WIA) who motivated in shaping out the study.

I also thank Dr.Alexander John, Professor, Division of radiation oncology who gave ideas to improve the study. I also thank Dr.Ramanaiah, senior resident, who encouraged and helped me in completing this study. I also thank Dr.Vasanth Christoper Jayapaul, Consultant Department of radiation oncology Cancer institute (WIA) who cleared all my doubts and gave ideas for the study.

I also thank Mr Sam Deva Kumar,a medical physicist ,Department of medical physicswho helped me in clearing all my doubts and gave ideas for my study.

I thank my mom Mrs.Ananthi, my dad Mr.Kailasam, my beloved brother Mr. Prasanth and all my family members for their unending support and encouragement.

I thank all my teachers who were always the source of motivation. I express my gratitude to all my colleagues and all staffs in radiotherapy department who were unfailing in extending their support.

I am ever thankful to all patients who were a part of this study, and pray for their speedy recovery to their normal life. I thank Almighty, whose love on me, helped me to respect others love, and to love all equally.

Turnitin Document Viewer - Google Chrome

[https://www.turnitin.com/dv?o=577700206&u=1044047332&s=&student\\_user=1&lang=en\\_us](https://www.turnitin.com/dv?o=577700206&u=1044047332&s=&student_user=1&lang=en_us)

The Tamil Nadu Dr.M.G.R.Medical...
TNMGRMU EXAMINATIONS - DUE 30-...

Originality
GradeMark
PeerMark

PERIODICAL ASSESSMENT OF  
BY 201419103.MD RADIATION THERAPY DR PRIYADHARSINI D

turnitin
24%  
SIMILAR
--  
OUT OF 0

Match Overview

1	Lai, Yo-Liang, Shih-Ne...	8%
2	www.rcr.ac.uk	5%
3	Peter Remeijer. "Imagi...	2%
4	www.science.gov	1%
5	Samuelsson, A.. "Syst...	1%
6	Submitted to Sheffield ...	1%
7	www.dtic.mil	1%
8	Budgell, G.. "Intensity ...	1%
9	www.onk.ns.ac.yu	1%
10	Submitted to Institute ...	<1%
11	www.answers.com	<1%

PERIODICAL ASSESSMENT OF PATIENT RELATED  
  
FACTORS AND SETUP ERRORS THAT AID IN  
  
REPLANNING IN HEAD AND NECK CANCERS  
  
  
A PROSPECTIVE STUDY

18

A dissertation submitted to The Tamilnadu Dr. M.G.R. Medical University,  
Chennai In partial fulfillment of the requirements for the award .The degree of  
**DOCTOR OF MEDICINE (M.D.) IN RADIO THERAPY** April 2016

# **TABLE OF CONTENTS**

## **I. Introduction:**

- 1) IMRT in head and neck cancers
- 2) Concept of adaptive radiotherapy.
- 3) An overview of setup errors
- 4) Anatomy of oropharynx, hypopharynx, nasopharynx.
- 5) Review of literature

## **II. Objectives and methodology**

- 1) Aim of the study
- 2) Objectives
- 3) Materials and methods.

## **III. Results and analysis**

## **IV. Discussion**

## **V. Conclusion**

## **VI. Reference**

## **ABSTRACT**

# **PERIODICAL ASSESSMENT OF PATIENT RELATED FACTORS AND SETUP ERRORS THAT AID IN REPLANNING IN HEAD AND NECK CANCERS A PROSPECTIVE STUDY**

**Dr.Priyadharsini.D.K, Cancer Institute (WIA)**

**Aim:** To analyse the effect of body mass factors before radiotherapy and changes occurring on course of radiation leading to setup error in patient with head and neck cancers and need of replanning.

**Materials and methods:** This is the prospective study and clinical data of 50 patients with oropharynx, hypopharynx, nasopharynx cancer was analyzed using daily on-line 2D KV image. BMFs included weight, height, circumference and thickness of neck. Alterations in the Body mass factors during treatment were

recollected from CBCT at 10th and 20th fractions. Repeat CT for RT planning done at 40 Gy for all patients. The initial CT and replan CT were registered and the structures contoured in initial CT were copied to replan CT to analyze the dose volume effect and NTCP if no Re CT and replan was done. Using BMFs the effect of the factors on magnitude of displacement was statistically analyzed.

**Results:** Higher body weight before radiotherapy was associated with greater setup errors. Among the ratios of the body mass factors during radiotherapy, the measures at the level of mastoid tip at 20th fraction were associated with more setup error. TCP was significantly better and NTCP was significantly reduced.

**Conclusion:** For the patients who have large reduction ratio in circumference ( $<1$ ) and thickness ( $<0.94$ ) at the level of mastoid tip at 20th fraction we should consider adaptive radiotherapy which improves TCP and decreases NTCP.

**Key words:** Body mass factors, setup errors, adaptive radiotherapy.



## **I.INTRODUCTION**

Radiation therapy concomitantly with chemotherapy is a choice of multi-modality treatment for head and neck cancer. Intensity modulated radiation therapy (IMRT) has become common now a days because we can achieve target dose with sparing of normal tissues. But we should be careful in patients' setup accuracy as IMRT causes steep dose gradients. In head and neck cancers correct fitting of the immobilization device, change in body contours, and treatment-induced changes such as tumor regression and cell death, tumor growth resulting from accelerated repopulation, weight loss due to emaciation or weight gain because of changes in appetite caused by radiation, concomitant chemotherapy, normal tissue fibrosis, all lead to setup abnormalities during course of radiation. Causes might be independent or related to the others. Insufficient compensation for these uncertainties leads to target under dosing and overdosing of nearby OARs, whereas overcompensation for uncertainties leads to unnecessary irradiation of normal tissue and constraints in treatment planning. This creates a tradeoff between tumor control probability (TCP) and normal tissue complication probability (NTCP) and emphasizes the role of minimizing uncertainties to enhance the therapeutic ratio of radiation. Daily Online image guidance helps in correcting these setup uncertainties. But IGRT is not always feasible. For patients with anatomic changes

due to tumor shrinkage or weight loss adaptive radiotherapy is considered. But increased costs, higher staff workload, and higher radiation doses to the patients should also be considered. So still we have to evaluate the need of suitable indications for adaptive radiotherapy in head and neck cancers.

Radiation therapy (RT) is the use of ionizing radiation as a part of cancer treatment to control tumor cells. Etymology: In Latin radiare means to emit rays; and in Greek therapeia means treatment. Thus Radiation is the treatment of malignancy by using ionizing radiation to deter the proliferation of malignant cells. The origin of radiotherapy followed on from three major scientific discoveries late in the 19<sup>th</sup> century: the discovery first of x-ray by the famous German physicist, Wilhelm Conrad Roentgen in 1895, then radioactivity by Henry Becquerel in 1896 and Radium by Madame Curie in 1898.

Radiation varies in types and mode of delivery also differs.. The various types of ionizing radiation used in radiotherapy are X-radiation, gamma radiation, electrons, protons and neutrons, of which gamma rays and high energy X-rays are in common practice. Ionisation is the process by which cancer cells are killed.. Direct action of radiation kills cancer cells immediately but indirect action is the


predominant one. Eventhough radiation kills both cancer cells and normal tissues most of the normal tissues will recover from effect of radiation.

## **BASIC PRINCIPLE OF RADIOTHERAPY**

Radiotherapy aims to deliver uniform dose distribution to the target volume which includes the tumor (GTV), sub-clinical spread of tumor cells (CTV) and margin to account for patient movement (PTV), organ movement and day-to-day variations in patient set-up. Hence we should keep radiation dose to normal tissues to low as possible. Hence more efforts should be done to deliver more accurate dose to target volume.

### **Conventional External Beam Radiotherapy:**

Conventional EBRT is delivered by beams of square or rectangular shape. This technique is well established and is generally quick and reliable. The limitation is the escalation of dose to tumor is limited due to the tolerance limit of the nearby critical organs.



**conventional RT showing rectangular beam shaping**

### **Three Dimensional Conformal Radiation Therapy:**

Three dimensional conformal therapy (3D CRT), is based on 3D anatomic information and use dose distribution that conforms dose to the target volume to t and to keep minimum possible dose to normal tissue. The beams are shaped with Multi Leaf Collimator controlled by computer system. The irregular shaped fields provide better avoidance of normal tissue.

MLC



The main distinction between treatment planning of 3D CRT and that of conventional radiation therapy is that the former requires the availability of 3D anatomic information and a treatment planning system. The important milestone which sparked in a revolution in not only radiological diagnosis but also in radiotherapy was the invention of x-ray CT. CT was introduced to the radiotherapy process at the end of 1970's and this resulted in 3D treatment planning, now a standard tool in radiotherapy. The anatomic information is obtained in the form of closely spaced transverse images, which is processed to reconstruct anatomy in any plane, and in three dimensions. Depending on the modality which we image critical structures and visible tumors are outlined slice by slice using planner.

### **Limitations of 3D CRT:**


Traditional radiation techniques, including 3D CRT, do not provide a method for sparing critical structures that push into and are partially or fully surrounded by a target. To overcome this problem new treatment methods are introduced in external radiotherapy. The intensity modulated radiotherapy provided more conformality than any other technique.

## **1) INTENSITY MODULATED RADIATION THERAPY (IMRT):**

The first clinical IMRT treatment delivery was in 1994 with serial tomotherapy device and then MLC-based IMRT, which was first implemented into clinical use at Memorial Sloan-Kettering Cancer Center in 1995.

The IMRT technique is most advanced forms of conformal treatment which improves Tumor control probability and decreases normal tissue complication probability. It is based on inverse treatment planning for determination of the required intensity modulated beams and on 3-D multi-modality imaging to define the target volumes. Focusing a higher radiation dose to tumor while minimizing radiation exposure to surrounding normal tissues is possible using IMRT. IMRT also has the potential to reduce treatment toxicity, though doses are not escalated.

Manipulation of intensities of individual beamlets within each beam is the most important advantage of IMRT thereby enabling customized dose distributions. In particular, IMRT provides better normal tissue sparing by its ability to produce non uniform fluence and hence can generate concave shaped dose distributions. Beam comprising a combination of deliberately modified intensities form an intensity modulated beam (IMB) and treatment delivered by such a beam is called intensity modulated radiotherapy (IMRT).



## CONCEPT OF INTENSITY MODULATION

### Basic Modes:

IMRT treatments is delivered with the MLC operating in one of two s modes:

1. The segmented MLC –Step and shoot method.
2. The dynamic MLC (DMLC) mode,-Sliding window technique

In step and shoot method the intensity modulated fields are delivered with a sequence of small segments or subfields, each subfield with a uniform intensity. The beam is turned on only when leaves are stationary in each given subfield position.

In the dynamic MLC mode -Sliding window technique the intensity modulated fields are delivered in a dynamic fashion with the leaves of the MLC moving during the irradiation of the patient.

1. First we have to do treatment planning and delineate target and normal structures.
2. Then we have to do Image guidance and treatment verification using electronic portal imaging device which corrects using matching of bony anatomy and reference markers.
3. PET Scan and CT scan are used during follow up for assessment of tumor response using geometric calculation.

#### **IMAGE MODALITIES AVAILABLE:**


1. KV X-Ray imaging using OBI
2. MV imaging using EPID.
3. Fan beam CT
4. MV CBCT-Used for image guided application on conventional accelerators.
5. KV CBCT-It is used for bony anatomy.
6. MRI-Fused with CT.
7. PET-Mainly used for lung cancers, also used in nasopharyngeal cancers.



8. US-has only limited accuracy.

9. SPECT.

### **DIGITALLY RECONSTRUCTED IMAGE**



### **SIMULATOR:**

1. Reference KV image in planned treatment position.
2. For comparing pretreatment verification the reference image should be compared with planned image.

### **CT SIMULATOR AND VIRTUAL SIMULATION SOFTWARE:**

1. It is used for virtual simulation procedure.
2. For geometric verification digitally reconstructed images are used.

**TPS:**

1. For Importing CT/MRI/PET CT data for planning treatment.
2. Image for geometric verification is image of CT simulator.

**ELECTRONIC PORTAL IMAGING DEVICE:**

1. They are taken during treatment delivery using MV treatment beam.

**FILM:**

1. They are traditional radiographic medium taken during treatment delivery using MV beam used for treatment.
2. Similar to diagnostic radiology a film cassette loaded with radiochromic film is placed in the beam exit of the patient.

**COMPUTED RADIOGRAPHY:**

1. The plate which is insensitive to ambient light and reusable is placed inside a traditional cassette.
2. Digital radiographs are made by reading the photographic plates in a special reader.

**IMPLANTED MARKERS:**

1. Fiducial markers of bio-compatible elements like gold seeds or gold wire coils are placed inside the target volume, preferably in soft tissues
2. They are seen in portal images taken with film and EPIDs.

### **IN ROOM ULTRASOUND:**

1. Used for visualizing soft tissue
2. Real time positioning of the target volume can be carried out using ultrasound imaging on the treatment couch prior to treatment.

### **IN ROOM KV IMAGING:**

1. Floor and ceiling mounted diagnostic X ray tubes and image intensifiers to give orthogonal images.
2. Both static and dynamic images are taken to verify patient setup before and after treatment delivery and necessary adaptations can be done in the treatment plans on an on-line basis.

### **INROOM CT IMAGING:**

1. The CT-On rails is advanced technique where a common couch is shared between the treating LINAC and the CT machine and the CT machine moves through the couch to acquire CT images just prior to treatment execution.

### **KV CBCT:**

1. An advanced amorphous silicon detector and a KV X-source are attached to the gantry of the treatment machine such that the KV and MV beams are orthogonal to each other.

2. CBCT of the entire volume of the region of interest of treatment shall be scanned and a half-beam scan or a full beam scan can be used depending on the diameter of the volume to be imaged.

### **MV CBCT:**

1. Megavoltage therapy X beam itself or a dedicated 1MV X beam can be used to take CBCT images using the EPID attached to the treatment gantry.
3. Since the isocenter is same for both imaging and treatment, an entire volume of interest shall be imaged with single setup with much ease.

### **CONE BEAM SIMULATOR:**

1. This is identical to the treatment machine.
2. Cheaper solution and a substitute for relatively costlier KV fan beam CT simulation where the image resolution is inferior to fan beam CT as the slices are reconstructed from the volume image information obtained.

### **TOMOTHERAPY:**

1. Tomotherapy incorporates the technology used in fan beam CT machines and hence getting the advantage of n number of rotations without the limitations as we have in other modern LINACS.
2. This is achieved by replacing a KV source with a MV source to rotate around the couch which moves in during beam ON to provide speedy delivery of

treatment and the binary MLCs takes care of the modulation required to provide the intensity modulation.

### **SURFACE AND MARKER TRACING:**

1. It measures optically the position of markers placed superficially on the patients' skin relative to reference a point.
2. Light of optical or infrared wavelength used.
3. This is performed continuously throughout the treatment delivery and setup and no radiation exposure associated with this.

### **MR LINAC/MR COBALT SOURCE:**

1. Uses very high quality soft tissue imaging principle of magnetic resonance and used for image guidance during delivery of treatment.


### **GATING:**

1. It is a method of assessing respiration during treatment delivery.
2. By Tracking the movement of external surrogates during course of treatment which indicates when target volume is centered on treatment isocentre.
3. A relation between external surrogate marker (usually a six dot IR reflector) and the movement of internal organs were established.

## **2) ADAPTIVE RADIOTHERAPY:**

For a range of clinical radiotherapy cases, the treatment plans optimized based on the initial set of computed tomography (CT) images become suboptimal for subsequent irradiations due to deformations of the relevant structures. The central idea behind Adaptive Radiotherapy (ART) is that adaptation of a treatment plan over the entire course of radiation treatment can, result in better therapeutic ratios than those that would have resulted from delivery of the initial single treatment plan. In routine practice, treatment plans are done with single CT image set acquired prior to the treatment course and that plan is usually evaluated using DVHs. DVHs based on a single scan may incorrectly estimate the delivered dose. Typically in response to weight loss or other “significant” morphological changes, plans are adapted for patients.

Adaptive radiotherapy is being practiced around the world in various forms. Re-Plan based on Re-CT after therapeutic dose of at least 40Gy is one of the most common techniques of ART being practiced.




For sites involving intra-fractional movements of the organs at risk and the target itself, such as esophagus, a four-dimensional CT is acquired and it is binned into a nominal 10 phase CT series. Plans for each phase are generated in the treatment planning systems and based on the CTV position on a particular day of treatment

which is obtained from CBCT acquired prior to the treatment delivery the corresponding best suited phase treatment plan is treated.

In pelvic site tumors such as cervix and prostate, the rectal and bladder fillings make a significant change in the target positions and this can be assessed based on the daily CBCT acquired prior to the treatment and necessary changes in plan chosen for delivery or repositioning the patient.

ART and image guided radiotherapy has become interlinked and hence modern radiotherapy delivery machines with advanced imaging technologies are widely preferred to deliver a better clinical results in patients.





### **3) AN OVERVIEW OF SETUP ERRORS:**

#### **GEOMETRIC UNCERTAINTIES IN RADIOTHERAPY:**

##### **DELINEATION ERRORS**

Misplacement in delineated contour with respect to tumor. Error in target volume delineation may be the single largest error in the whole radiotherapy chain in modern radiotherapy protocols.

##### **PLANNING ERRORS**

These errors are caused by wrong beam set up and wrong margins to the CTVs and GTVs due to uncertainties in the contouring process using single modality images. By proper quality assurance and regular verification of plans by physicists may help in eliminating these such errors.

##### **ORGAN MOTION:**

This error is mainly due to the movement of tumor with respect to bony landmarks. It occurs either during treatment planning or treatment execution.

##### **SETUP ERRORS:**

A shift in the isocentric position when an image is compared against its corresponding reference i.e., the calculated deviation between actual and expected

position is known as set-up error. To maintain correct direction information on shifts, vector calculations are done and shifts in anterior directions are given positive sign whereas shifts in posterior directions are negative sign. Types of setup errors 1.Gross error 2.Systematic error 3.Random error

Gross error is defined as an unacceptably large set-up error that could underdose part of the clinical target volume (CTV) or overdose an organ at risk. As the CTV to PTV treatment margins do not account for errors of such magnitude, gross errors need to be corrected earlier to the commencement of treatment.

Systematic error is defined as the error which occurs for each fraction throughout the treatment in same direction and similar magnitude.

Possible cases of gross errors are

- 1.Incorrect patient.
- 2,Incorrect patient orientation.
- 3.Incorrect anatomical site.
- 4.Incorrect field size.
- 5.Incorect field shape.
- 6.Incorrect isocenter position of unacceptable magnitude.

The preferred method to correct gross error is to image on the first treatment fraction immediate to treatment delivery.

In general, a 10mm error is taken as the level for action in a wide range of sites.

## **SYSTEMATIC ERROR:**

It is the deviation that occurs in same direction and is of similar magnitude for each fraction throughout the treatment course.

It is classified into individual and population systematic error.

## **INDIVIDUAL SYSTEMATIC ERROR:**

The systematic error of the individual Patient is the mean error over the course of treatment.

## **POPULATION SYSTEMATIC ERROR:**

It is the systematic error for the group of patients.

It is calculated as the standard deviation of mean errors for each patient.

Causes of systematic error may be:

1. Target delineation error: the difference between ideal CTV and the delineated CTV is considered as target delineation error
2. Target position and shape: when the position of target contoured and planned differs from that of the shape and position during treatment.

### 3. Phantom transfer error:

It is accumulated when transferring image data from initial localization through TPS to the linear accelerator.

They are classified as systematic because causes of phantom transfer do not change and it varies slowly (isocentre position and leaf accuracy positions).

The causes includes differences in

- 1.Laser alignment between CT and linear accelerator.
- 2.CT couch longitudinal positional indication.
- 3.image resolution.
- 4.margin growing algorithm.
- 5.Field edge and MLC leaf position.
- 6.isocentre location.
- 7.source to surface distance indication.
- 8.gantry and collimator angle accuracy.

They are corrected by quality assurance by adequate routine check outs. We should ensure that any differences lie within  $\pm 2\text{mm}$  for a distance  $\pm 1$  degree for angle indication.

Patient setup error:

Causes include:

1.change in patient position.

2.change in shape or size(eg..weight change,hair loss)

3.Movement of target relative to skin marks caused by CT scan and

treatment performed on different treatment couches

It is the only one possible part of overall systematic setup error.

### **RANDOM ERROR:**

It is a deviation that can vary in any direction and magnitude for each delivered fraction of treatment.`

It is classified into individual and population random errors.

#### **Individual:**

It is the standard deviation of the measured errors during the delivery of treatment in each fraction.

#### **Population random error:**

It is calculated for group of patients as the mean of individual random errors.It usually occurs at treatment delivery stage and hence called execution errors.

#### **Types of random errors:**

##### **1.Patient setup error:**

They are unpredictable changes occurring from change in patients position, treatment machine and setup difference between each delivered fraction.

## **2.Target position and shape:**

It accounts for motion between the treatments rather than from delineation to treatment.

## **3.Intrafraction errors:**

It's the change in the patient position and internal anatomy arising during delivery of single fraction eg:breathing

Offline correction strategy may not predict the random error part in subsequent fractions and hence treatment margins must be calculated to include these variations.

The individual mean set-up error is the mean set-up error for an individual throughout the treatment regimen and is calculated as the ratio of the sum of the measured set-up errors for each fraction to number of imaged fractions. It can be expressed by the formula:

$$m_{individual} = \frac{\Delta_1 + \Delta_2 + \Delta_3 + \dots + \Delta_n}{n}$$

Overall population mean for the analyzed group of patients is a strong indicator of any given treatment technique and it should be ideally zero. It is calculated as the ratio of sum of the mean errors of the individuals of the group to the number of patients in the analyzed group. It can be expressed using the following formula:

$$M_{pop} = \frac{m_1 + m_2 + m_3 + \dots + m_p}{P}$$

Population systematic error is defined as the standard deviation of the individual mean set-up errors about the overall population mean. It's calculated as the square root of ratio of the sum of the squares of the differences between the overall population mean and individual patient mean to the total number of patients minus one. It can be expressed as follows:

$$\sum_{set-up}^2 = \frac{(m_1 - M_{pop})^2 + (m_2 - M_{pop})^2 + (m_3 - M_{pop})^2 + \dots + (m_n - M_{pop})^2}{(P - 1)}$$

The individual random set-up error is a measure of the standard deviation of the setup errors around the corresponding mean individual value. It is calculated as square root of the ratio of sum of the squares of the differences between the mean individual error and the set-up error from each image in turn to the total number of images minus one. Mathematically expressed as:



$$\sigma_{individual}^2 = \frac{(\Delta_1 - m)^2 + (\Delta_2 - m)^2 + (\Delta_3 - m)^2 + \dots + (\Delta_n - m)^2}{(n - 1)}$$

Population random setup error is the mean of all the individual random errors. It is calculated as the ratio of sum of all the individual random errors to the total number of patients assuming that all patients are imaged similar times.


It is mathematically expressed as:

$$\sigma_{set-up} = \frac{\sigma_1 + \sigma_2 + \sigma_3 + \dots + \sigma_p}{P}$$

**Diagram of the impact of geometrical deviations on dose distribution:**


**(a) random errors lead to blurring of dose distribution**

**(b) systematic errors lead to shift of the cumulative dose distribution relative to CTV**



## WORKFLOW OF RADIOTHERAPIC CHAIN-STEPS

### CHECKED WITH EPID



### Measurement of Geometrical Errors and its Correction:

Geometrical errors measurement is important for definition of margins. The more important one to correct is systematic error because it has more effect on magnitude.

**1.Target volume delineation** – It is measured by multi-observer studies and is reduced by clear protocols such as RTOG, training and consultation and multi-modality imaging without relying on single modality image information .

**2.Organ motion:**

Tumor motion is measured by CT ,markers detected through X ray,EPID.USG and CBCT are also used recently for tracking of tumor.We can correct this by gating,good treatment and CT scan protocols.The most effective way to reduce this is adaptive radiotherapy using daily online imaging for atleast first few fractions which helps in achieving smaller systematic errors.

**3.Setup errors:**

Portal imaging helps in reducing setup errors.For this portal image is compared with simulation image and matching should be done.Best way is compare DRR with portal image.Bony landmarks kept as guidance and matched with DRR.On line and offline review should be done and errors are measured and corrected.


**Random and systematic errors.**

**Each group of points represents the fractions of single patient.**

**The scatter within a group is day-to-day variation.**

**The group average (the five larger squares) is the systematic error of a patient.**

**The mean of all patient averages is indicated by the large yellowish orange square and this is the overall mean.**




The effect of setup displacement on the dose distribution relative to CTV. Random deviations leads to a blurring of the dose distribution. Systematic deviations lead to shift in the dose distribution relative to the CTV.

If uncorrected the systematic error remain throughout the course of treatment thereby compromising dose coverage to the CTV.

Verification is needed to ensure that systematic displacement lies within tolerance levels.

Offline review corrects systematic errors during treatment and only remaining thing is random error.



## **HOW TO CREATE GEOMETRIC VERIFICATION PROCESS:**

The verification process should consider

1. Personnel, responsibility and training.
2. Equipment and technical infrastructure.
3. Imaging protocols

- Imaging

- Frequency ,time of imaging.

4. Measurement of setup errors

- systematic error

- Random error

5. Action levels, Tolerances and correction strategy.

6. For concomitant exposure dose measurements should be considered.

## **EQUIPMENT AND TECHNICAL INFRASTRUCTURE:**

1. Images should be in good quality and to be able to give information needed.
2. Effective connectivity is needed.
3. Clear conventions are required for coordinating system and error reporting.
4. Good quality assurance .
5. Uncertainties in verification process should be calculated.
6. For good complete verification process suitable software must be used.

## **PERSONNEL, RESPONSIBILITIES AND TRAINING:**

1. To set guidelines on structure and process a good verification team is required.
2. Assessment of training and competency are required.
3. For each institute a risk analysis should be done.

## **IMAGING PROTOCOLS:**

1. Image acquisition depends on quantity of target anatomy seen within the field.
2. Timing of image acquisition should be ideal.
3. At least two orthogonal images are required to verify image in all directions.
4. To assess systematic error for radical treatment at least three to five imaging sets are needed.
5. Site and treatment technique decides number of fractions to be imaged.

## **MEASUREMENT OF SETUP ERRORS:**

1. Prior to first treatment gross error should be detected.
2. Individual systematic setup error should be calculated and minimized.

## **SUMMARY, TOLERANCES, ACTION LEVELS AND CORRECTIVE**

### **STRATEGIES:**

1. Gross errors must be corrected as soon as possible.
2. Radiotherapy department in each institute have to evaluate their tolerances



3. Tolerances used in imaging protocol depends on

- a. Anatomical site
- b. The technique of treatment.
- c. CTV-PTV margin.
- d. At last the compliance of the patient.

4. What are the actions to be taken in treatment verification:

- a. Further repeat imaging if it was a simple random error.
- b. Systematic error reassessment.

5. Corrective strategies:

- a. Needs accurate calculation of systematic setup error.
- b. Then the chosen correction strategy should be applied to remove the error.
- c. Corrections applied to treatment setup must be verified.
- d. Weekly imaging is necessary.


### **DOSE CONSIDERATIONS:**

- a. Dose accumulation due to concomitant exposures and treatment accuracy using imaged information should be optimized.
- b. It is better to setup and image correctly to ensure adequate and accurate coverage of target volume and to avoid risk associated with additional exposure.

## RELATIONSHIP BETWEEN CTV-PTV TREATMENT MARGIN AND TREATMENT VERIFICATION

CTV-PTV margins is influenced by both systematic and random errors.

Using online imaging treatment is verified and quantified to reduce sources causing errors and to reduce applied margin.



## **APPROPRIATE PROTOCOL FOR HEAD AND NECK VERIFICATION:**

### **On fraction 1-Before starting treatments:**

- 1.Orthogonal images to be taken to minimize dose to the critical structures.
- 2.Acquire images for all possible treatment fields if field edge verification is needed.
- 3.Verify and correct gross errors immediately.

### **On fraction 2 and 3**

To take orthogonal images and assess each image against tolerance level set and correct gross errors.

### **Action before fraction 4**

- 1.Calculate systematic error in AP,SI,ML directions.
- 2.If setup error is more than the action level we have to apply systematic setup error correction.


### **Fraction 4 and 5**


If setup is corrected then do repeat imaging.

If practical then calculate the new overall systematic setup error and correct values greater than action level.

### Weekly and first day of each phase of treatment plan:

- 1.To take orthogonal image each week.
- 2.Correct gross errors for each fraction whenever necessary.
- 3.If setup error significantly differs then do repeat imaging.
- 4.Apply systematic setup error correction if needed.





## **OTHERS:**

\*Immobilisation is strictly necessary.


\*Impact of organ motion of tongue and larynx considered.

\*Isocentre should be verified using anterior, posterior and lateral views.

\*Bony anatomy should be clearly taken in the images taken.

\*Tumors planned with very small margins or hypofractionated treatment are daily verified with images.

## **ANATOMIC STRUCTURES SHOULD BE MATCHED:**



## **EVIDENCE FOR HEAD AND NECK TREATMENT VERIFICATION GUIDELINES:**

### **IMMOBILISATION AND APPROPRIATE SPATIENT POSITIONING:**

a) Low and high melting point thermoplastic masks.

b) Bite blocks.

Tumor shrinkage and weight loss leads to change in patients anatomy and ill fitting immobilization device over the course of treatment.

GTV decreases by 1.8% if there is large nodal mass at the start of treatment.

These patients should be considered for remoulding and replanning at 3<sup>rd</sup> or 4<sup>th</sup> week of treatment .

### **SETUP REPRODUCIBILITY:**

More effective immobilization produces good setup reproducibility. Moulds should not be used immediately after preparing because there is shrinkage of 2mm in the first 24 hours.

If the field covers the lower neck and supraclavicular fossa shoulders should be matched exactly where more differences occur.

### **4)ANATOMY**

#### **OROPHARYNX:**

Anteriorly-oral cavity.

Posteriorly-larynx and hypopharynx.

Superiorly -nasopharynx.

Subsites:Tonsil,Base of tongue,soft palate.

Tonsil-consists of anterior and posterior tonsillar pillar between them there is cleft where palatine tonsil is located.

**Base of tongue**-comprises of posterior 1/3 of tongue

Borders- Anterior-circumvallate papillae in front of sulcus terminalis.

Posterior-inferior-hyoid and epiglottis.

Laterally-glossopharyngeal sulci.

**Lingual tonsil present under base of tongue.**

**Vallecula-** is a 1 cm mucosal strip between base of tongue and epiglottis.

Sensory innervation of the base of tongue is glossopharyngeal nerve.

**Soft palate-**fibromuscular structure

Boundaries:

Anterior-hard palate.

Lateral-anterior tonsillar pillar

Midline-uvula.

Posterior-inferior-free edge.

Components of soft palate-levator veli palatini,

palatoglossus, palatopharyngeus, musculus uvulae.

Muscles of soft palate supplied by pharyngeal plexus.




**Lymphatic spread:**

**Most common-ipsilateral level II.**

**Order of metastatic progression:**

Level I/II superiorly → midcervical(level III) → lower  
cervical(level IV) inferiorly..

### ANATOMY OF OROPHARYNX



## **HYPOPHARYNX**

Behind the Larynx (in front of 3rd to 6th Cervical vertebra) From the tip of epiglottis superiorly to the lower border of cricoid cartilage inferiorly

Communicates: - Anteriorly with the Larynx ,Superiorly with the oropharynx  
Inferiorly with the esophagus

The hypopharynx does not only lie behind the larynx but also Projects laterally on each side of the larynx So it is formed of : Postcricoid region ( behind the larynx) -  
Two pyriform fossae and posterior pharyngeal wall.

## **PYRIFORM SINUS**

Shape : inverted pyramid.

Extent: -Superiorly: epiglottis .

Lateral: thyroid cartilage

Medial: arytenoid cartilage; aryepiglottic fold.

Posteriorly: open & continuous with posterior pharyngeal wall.

Apex: meeting of anterior, lateral &medial wall inferiorly

## **POST CRICOID REGION**

Pharynx mucosa covering post. Surface of cricoid

Pharynx become continuous with esophagus at post cricoid region

Extent:

Superior: arytenoids

Inferior: oesophagus

## **POSTERIOR PHARYNGEAL WALL**

Cover middle & inferior constrictor muscles.

Separated from prevertebral fascia by retropharyngeal space.

Extent: Superiorly: upper border of epiglottis

Inferior: lower border of cricoid

Sideways: apex of one pyriform sinus to other.

### **Nerve supply of hypopharynx**

Internal branch of superior Laryngeal nerve :vagus(X)

Glossopharyngeal nerve :(IX)

sensory: External branch of superior Laryngeal nerve (X) Recurrent laryngeal nerve (X) Pharyngeal plexus (IX) motor

## **LYMPHATIC DRAINAGE**

Deep cervical lymph node : level 2,3& 4

Prelaryngeal & paratracheal lymph nodes: level 6.

Retropharyngeal node -Node of rouviere at skull base.

**POST CRICOID AREA:** The hypopharynx leading to upper oesophageal sphincter. Occasionally brisk opening seen upon laryngeal examination . Upper oesophageal sphincter opening- upon rigid oesophagoscopy.

## **CARCINOMA HYPOPHARYNX**

Constitute 5.2% of upper aerodigestive tract cancer.

Mostly squamous cell carcinoma of hypopharynx.

Mean age of presentation 65 years

Common stage of presentation : stage III& IV -POOR PROGNOSIS

### **INCIDENCE OF HYPOPHARYNX CARCINOMA.**

65-75%-pyriform sinus carcinoma

5-15% - post cricoid carcinoma.

10-20% -posterior pharyngeal carcinoma.

### **RISK FACTORS OF CARCINOMA HYPOPHARYNX**

Age & Sex: carcinoma pyriform fossa- male above 40 years

Carcinoma postcricoid region: females 20 to 40 years

Carcinoma posterior pharyngeal wall : males above 50 years

Family history -Tobacco ,Alcohol

Exposure : polyaromatic compounds ; asbestos & welding fumes

Nutritional deficiency. VIT A & E. iron, Carotenoids and flavonoids.

### **RISK FACTORS OF CARCINOMA HYPOPHARYNX**

infections; HPV (20–25% only positive for HPV DNA & Ab against HPV 16 E6 & E7)

Associated diseases: PLUMMER VINSON SYNDROME

GENETIC: P53 & EGFR mutation -Synchronous & metachronous malignancy.

## **FIELD CANCERIZATION**

Hypopharynx Carcinoma occur within field of diseased mucosa .Carcinogens induce dysplastic changes in mucosa of the upper aero digestive tract. Increased risk of malignancy

## **CARCINOMA OF PYRIFORM SINUS**

Age:40 years

presentation: late; Metastatic neck nodes

Spread: local Upwards: base of tongue Downwards: post cricoid region Medially: AE fold and ventricle Laterally: thyroid cartilage, -Lymphatic spread: upper and middle group of jugular cervical nodes -Distant metastasis: occur late and may be seen in lung, liver, bone

## **CARCINOMA OF POST CRICOID REGION**

Plummer-Vinson syndrome age group of 20-40; female Progressive dysphagia

Voice change Weight loss

Spread: local spread - cervical oesophagus, arytenoids

Lymphatic spread - paratracheal nodes, may be bilateral due to midline nature of lesion

## **CARCINOMA OF POSTERIOR PHARYNGEAL WALL**

Mostly seen in males above 50 years of age

Clinical features: dysphagia, metastatic neck node

Spread: local - prevertebral fascia, muscles and vertebrae

Lymphatic: usually bilateral, retropharyngeal and deep cervical nodes involved

### **CLINICAL PRESENTATION**

Hoarseness of voice: vocal cord fixation

Stridor: mass effect on trachea


Weight loss. Anemia, malnutrition, Throat pain, Sore throat dysphagia

Odynophagia ,pooling of saliva


Referred otalgia: cause int. laryngeal nerve (X) Neck mass: metastatic neck node

Direct extension most frequent presenting symptoms include a neck mass (either representing the tumour or nodal metastases .

## ANATOMY OF HYPOPHARYNX



## STAGING OF HYPOPHARYNGEAL CANCER:



## **CLINICAL EVALUATION**

History taking

General physical examination

Oral hygiene & dentition

Airway status

Status of speech & swallow.

Complete examination of oral cavity , oropharynx.

Examination of neck nodes.

Indirect laryngoscopy

Direct laryngoscopy

## **EXAMINATION OF NECK NODES**

Location ,Size ,number ,Mobility ,Tenderness ,Relationship with adjacent structure.

Examination of neck nodes: sub mental(Ia) & submandibular(Ib)

Examination of neck nodes: upper.,middle & lower deep cervical (ii; iii. iv)

**INDIRECT LARYNGOSCOPY** -mirror warmed; check temp. -Hold tongue -

Introduce mirror into the oral cavity facing downwards - mirror brought to rest against the uvula -do not touch the posterior pharyngeal wall - laryngeal inlet is visualized,

Structures seen on indirect laryngoscopy (in order):



Base of the tongue ,Vallecula ,Median and lateral glossoepiglottic folds

Epiglottis ,Vestibular fold ,True vocal cords ,Trachea ,Laryngeal cartilage

### **PRE TREATMENT EVALUATION:**

To assess extent of tumor Relation with other structure Involvement of larynx

Mobility of vocal cords

Direct laryngoscopy

Oesophagoscopy

Bronchoscopy

Panendoscopy

Chest x ray :infection; malignancy;metastasis

HRCT : thickness, invasion, L.N metastasis

MRI :soft tissue details, tissue edema

PET :residual or recurrent tumor after RT

### **NASOPHARYNX:**

It is a cuboidal chamber.

Boundaries:

Anteriorly:continuous with nasal cavity via posterior choanae.

Inferiorly-oropharynx.

Roof-basilar portion of sphenoid and occipital bones.

Floor-superior surface of soft palate and nasopharyngeal isthmus.


Lateral- Eustachian tube


Lateral wall contains fossa of rosenmuller –most common origin of malignancy.

Nerve supply-sensory-maxillary division of trigeminal nerve and glossopharyngeal nerve.

Motor-glossopharyngeal nerve,vagus nerve and sympathetic fibres from superior cervical ganglion.

## ANATOMY OF NASOPHARYNX





## REVIEW OF LITERATURE:

BMF such as body weight, body height, and the circumference and bilateral thickness of the neck of patients were taken from the online Kilo-voltage CBCT acquired using the on-board imager and assessment of setup errors by systematic error (SE) and random error (RE) through the superior-inferior (SI), anterior-posterior (AP), and medial-lateral (ML) directions, and couch rotation (CR). The magnitude of the effect of BMF could be calculated using Mann–Whitney U test. Among the ratios of the BMFs during radiotherapy, the values at the level of mastoid tip at the 20th fraction were associated with greater setup errors.

Deviation between intended geometry of radiotherapy plan and real geometry of radiotherapy treatment were presented as geometrical errors. Buildup of smaller

errors, which can be generally classified as set-up, organ motion, organ delineation, and technical condition related errors is the total geometrical error. The amount of systematic and random component of these errors should be encountered in treatment planning process and a clear distinction must be made between them. The amount of most of geometrical errors can be predicted, minimized, and kept under control if errors are measured with EPID and proper correction strategy are deployed; the precision of treatment and consequent results can also be improved.

IMRT treatments are more sensitive to setup errors and so taking into account the systematic errors in treatment plans. A planning margin to account for set-up errors was added to the clinical target volumes and to the spinal cords and the part of the target covered with a dose  $>95$  and  $<105\%$  and the effect in the critical organs is dependent on the sharpness of the dose gradients outside the critical organ thereby it is plan quality dependent too.

The setup displacements and translational and rotational errors were taken into account from the online images acquired prior to treatment and based on that individualized margins for CTV, PTV was generated.

## **II)OBJECTIVE AND METHODOLOGY:**

### **1)AIM OF THE STUDY:**

To analyse the impact of body mass factors before radiotherapy and changes occurring during radiation leading to setup displacement in patient with head and neck cancers and need of replanning.

### **2)OBJECTIVE**

#### **Primary objective:**

By assessing degree of setup error and effects of Body Mass Factors on setup errors we can analyse the need of replanning and to assess whether these factors are really helpful in replanning and Adaptive radiotherapy .

#### **Secondary objective:**

- 1.TCP/NTCP ratio calculation .
- 2.Change in Body mass factors and need of replanning.
- 3.Impact of replanning

**Sample size:** 50.

**Study design:**Prospective

**Study period:** December 2014-October 2015.

**Inclusion criteria:**

All patients with

1. Age >30 years.
2. Both sexes
3. Sites included-Nasopharynx,oropharynx,hypopharynx.
4. Patients planned for definitive Chemoradiation/definitive radiation.
5. ECOG performance status-0-2
6. Informed consent from patient.

**Exclusion criteria:**

1. Patients with poor performance status.
2. Patients initially treated outside.
3. Patients who had initial surgery.
4. Patients with palliative intent treatment.

### **3)Methods and Materials:**

#### **Methods of Planning:**

1. Patients are immobilised with thermoplastic mask.
2. CT for RT planning done from Orbit to shoulder with 3mm cuts
3. Marks like leadshot are placed over patients surface using laser to facilitate accurate daily position.
4. For patients receiving definitive radiation CTV was defined as GTV+1-1.5cm margin. Guidelines for delineation of elective nodal CTV were followed. PTV was extended 3mm around CTV.
5. IMRT plans are generated.
6. Prescription dose will be 54 Gy to CTV and boost to high risk regions primary and involved lymph nodes of about Total dose 66 Gy.

#### **Method of Treatment verification:**

1. Patients are positioned on the couch according to reference marks already kept during planning.

2.Online On board imaging (2D KVCT daily and 3D CBCT at 10 th and 20 th fraction )were taken and registered with Digitally reconstructed radiographs from the treatment planning images.

3.Images are compared by correlation of bony anatomy and differences are corrected by shifting couch translationally before treatment.

4.Atleast 3 reference landmarks included-3 visible bony landmarks:

1.Vertebra of Cervical Spine.2.Nasal septum.3.Mandible profile.

### **Anthropometric Measurements of Body related Factors:**

#### **Patient related Factors:**

1.Performance score.

2.Age

3.Body mass factors.

4.Performance status:Scored according to ECOG.


5.Body mass factors included are a)BMI b)Circumference and thickness across three specified sections of head and neck.



Level A-Line drawn at level of Mastoid tip ,same section as the junction between skull base and 1 st cervical vertebra.

Level B –Line drawn based on mandible angle,same height as the junction between 2<sup>nd</sup> and 3 rd cervical vertebra.

Level C-Line drawn at level of thyroid notch ,same as the 5 th cervical vertebra.



— Level A

→ Level B

↔ Level C

3.Body mass factors will be recorded before RT and at 10<sup>th</sup> and 20<sup>th</sup> fractions during course of radiation.

4.Circumference and thickness values are retrieved from CT simulation images and Cone beam CT images at three specified levels during treatment.

5.Circumferences are calculated by brushing body contour at specified section with fixed thickness to generate volume, and then calculated volumes are divided by the contouring thickness to get the values of circumferences.

6.Thickness is calculated as the maximal transverse distance at same distance as circumferences.

7.Body mass index was calculated by dividing weight in kilograms by height in metre square.

8.Patients are monitored weekly and toxicities are recorded according to CTCAE.

9.Ratio of BMFs during RT are calculated at three levels.

**Ratio of Circumference at n<sup>th</sup> fraction =**

$$\frac{\text{Circumference at level A at n th fraction}}{\text{Pretreatment Circumference}}$$

## Patient characteristics before radiotherapy

Number	Variable	Values
1.	Age(years)	
	Median	54 years
2.	Weight(kg)	
	Mean	56.5 years
	Median	54 years
3	Height(cm)	
	Mean(range)	164.4 cm
	Median	165 cm
4	BMI	
	Mean(range)	23.2
	Median	22.8
5	ECOG PS	
	0	24
	1-2	26
6	CCRT/RT alone	
	CCRT	41
	RT alone	9

7	Tumor site	
	Oropharynx	18
	Hypopharynx	29
	nasopharynx	3
8	Circumference A(cm)	
	Mean $\pm$ SD	48 $\pm$ 2.6
9	Thickness A	
	Mean $\pm$ SD	15.1 $\pm$ 1.2
10	Circumference B(cm)	
	Mean $\pm$ SD	42 $\pm$ 2.8
11	Thickness B(cm)	
	Mean $\pm$ SD	13.2 $\pm$ 1.4
12	Circumference C(cm)	
	Mean $\pm$ SD	37 $\pm$ 4.2
13	Thickness C(cm)	
	Mean $\pm$ SD	11.5 $\pm$ 1.6

## **Set Up Displacement:**

Daily on board image taken and an offline image review should be done and setup errors are calculated in Anteroposterior,mediolateral,Superoinferior directions.s

For each direction systematic and random errors calculated.

Systematic error was the deviation between simulated patient position and average treatment position.Random error occurs between different fractions.By analysing all the alignment data before 25 fractions of treatment for every patient ,values of systematic and random errors for all AP,SI,ML directions are calculated.

## **Stastical Analysis:**

1.To determine the correlation between magnitude of errors and patient related factors are classified into two groups and .calculated using Mann-whitney U test.

2.To examine association between the reduction ratio of body weight and circumferences or thickness,displacement in different direction Pearson correlation coefficient is used.

AP-ANTEROPOSTERIOR

ML-MEDIOLATERAL

SI-SUPEROINFERIOR

SE-SYSTEMATIC SRROR

RE-RANDOM ERROR.

CR-COUCH ROTATION

Setup Errors (mean  $\pm$  standard deviation in mm) in AP,SI,ML directions according to low range and high range 50% percentile of body mass factors before RT

variable	AP-SE	AP-RE	SI-SE	SI-RE	ML-SE	ML-RE
<b>Weight</b>						
Lower	0.8 $\pm$ 0.4	0.8 $\pm$ 0.2	2 $\pm$ 0.8	1.1 $\pm$ 0.3	1.7 $\pm$ 0.7	1 $\pm$ 0.2
Higher	1.2 $\pm$ 0.5	0.8 $\pm$ 0.2	2.3 $\pm$ 0.9	1.7 $\pm$ 0.8	1.8 $\pm$ 0.5	0.9 $\pm$ 0.3
P value	0.045*	0.250	0.556	0.022*	0.426	0.450
<b>Height</b>						
Lower	1 $\pm$ 0.5	0.7 $\pm$ 0.3	1.8 $\pm$ 0.5	1 $\pm$ 0.2	1.7 $\pm$ 0.6	1 $\pm$ 0.3
Higher	1.2 $\pm$ 0.7	0.8 $\pm$ 0.3	2.5 $\pm$ 1	1.8 $\pm$ 0.8	1.8 $\pm$ 0.6	1 $\pm$ 0.3
P value	0.07	0.15	0.106	0.002*	0.26	0.82
<b>BMI</b>						
Lower	1 $\pm$ 0.4	0.7 $\pm$ 0.3	2.1 $\pm$ 0.9	1.3 $\pm$ 0.5	1.6 $\pm$ 0.7	1 $\pm$ 0.3
Higher	1.2 $\pm$ 0.7	0.8 $\pm$ 0.3	2.1 $\pm$ 1	1.5 $\pm$ 0.7	1.9 $\pm$ 0.5	1 $\pm$ 0.3
P value	0.17	0.506	0.924	0.208	0.304	0.924

Setup Errors (mean  $\pm$  standard deviation in mm) in AP,SI,ML directions  
according to low range and high range 50% percentile of body mass  
factors before RT

Variable	AP-SE	AP-RE	SI-SE	SI-RE	ML-SE	ML-RE
Circumference –A						
Lower	1 $\pm$ 0.4	0.7 $\pm$ 0.3	2 $\pm$ 1	1.3 $\pm$ 0.7	1.6 $\pm$ 0.8	1 $\pm$ 0.4
Higher	1.2 $\pm$ 0.6	0.8 $\pm$ 0.3	2.3 $\pm$ 1	1.5 $\pm$ 0.8	2 $\pm$ 0.5	1 $\pm$ 0.3
P value	0.335	0.485	0.304	0.186	0.344	0.411
Circumference –B						
Lower	1 $\pm$ 0.5	0.7 $\pm$ 0.3	2 $\pm$ 1	1.3 $\pm$ 0.7	1.6 $\pm$ 0.8	1 $\pm$ 0.4
Higher	1.2 $\pm$ 0.6	0.8 $\pm$ 0.3	2.3 $\pm$ 1	1.5 $\pm$ 0.8	2 $\pm$ 0.5	1 $\pm$ 0.3
P value	0.388	0.485	0.304	0.186	0.344	0.411
Circumference-C						
Lower	1 $\pm$ 0.5	0.8 $\pm$ 0.3	2.2 $\pm$ 1	1.3 $\pm$ 0.7	1.7 $\pm$ 0.7	1 $\pm$ 0.3
Higher	1.2 $\pm$ 0.6	0.8 $\pm$ 0.3	2.1 $\pm$ 0.7	1.6 $\pm$ 0.7	2 $\pm$ 0.5	1.1 $\pm$ 0.3
P value	0.47	0.566	0.967	0.334	0.240	0.672
PS						
0	0.9 $\pm$ 0.4	0.7 $\pm$ 0.3	2 $\pm$ 0.9	1.2 $\pm$ 0.3	2 $\pm$ 0.6	1.1 $\pm$ 0.3
1-2	1.4 $\pm$ 0.5	1 $\pm$ 0.3	2.5 $\pm$ 1.1	1.8 $\pm$ 1	1.6 $\pm$ 0.7	1 $\pm$ 0.4
P value	0.042*	0.015*	0.24	0.042*	0.071*	0.933

Setup Error (mean  $\pm$  standard deviation in mm) in AP,SI,ML directions according to low range and high range 50% percentile of body mass factors during RT (10th fraction)

VARIABLE	AP-SE	AP-RE	SI-RE	SI-RE	ML-SE	ML-RE
rT(level A)						
lower<0.98	1 $\pm$ 0.5	0.8 $\pm$ 0.3	2.3 $\pm$ 1.1	1.6 $\pm$ 0.8	2 $\pm$ 0.5	1.1 $\pm$ 0.4
higher>0.98	1.2 $\pm$ 0.5	0.9 $\pm$ 0.4	2 $\pm$ 0.8	1.3 $\pm$ 0.7	1.6 $\pm$ 0.6	1 $\pm$ 0.3
P value	0.184	0.283	0.843	0.421	0.223	0.043*
rT(level B)						
lower<0.97	1 $\pm$ 0.5	0.8 $\pm$ 0.2	2.1 $\pm$ 1	1.3 $\pm$ 0.4	1.7 $\pm$ 0.7	1.2 $\pm$ 0.3
higher>0.97	1.1 $\pm$ 0.7	0.9 $\pm$ 0.3	2.2 $\pm$ 0.9	1.5 $\pm$ 1	1.9 $\pm$ 0.6	0.9 $\pm$ 0.25
P value	0.665	0.917	0.462	0.447	0.324	0.018*
rBW						
lower<0.99	1.1 $\pm$ 0.5	0.9 $\pm$ 0.3	2 $\pm$ 0.7	1.4 $\pm$ 0.4	2 $\pm$ 0.7	1.1 $\pm$ 0.3
higher>0.99	1.1 $\pm$ 0.5	0.9 $\pm$ 0.3	2.1 $\pm$ 1.1	1.4 $\pm$ 0.8	1.7 $\pm$ 0.5	1 $\pm$ 0.3
P value	0.842	0.873	0.808	0.883	0.778	0.256


rT-ratio of thickness.

Bw-Body weight.

rC-ratio of circumference



Association between ratio of weight and thickness at level A during  
the 20th fraction of CBCT ( $r = 0.32$ ,  $p = 0.081$ ).



Setup Error (mean  $\pm$  standard deviation in mm) in AP,SI,ML directions according to lower and higher 50% percentile of body mass factors during RT  
(20th fraction)


Variable	AP-SE	AP-RE	SI-SE	SI-RE	ML-SE	ML-RE
rC(level A)						
lower	1.3 $\pm$ 0.5	1 $\pm$ 0.2	2.4 $\pm$ 0.9	1.8 $\pm$ 0.8	1.6 $\pm$ 0.7	1 $\pm$ 0.3
higher	0.8 $\pm$ 0.5	0.7 $\pm$ 0.3	2 $\pm$ 1	1.2 $\pm$ 0.4	2 $\pm$ 0.5	1 $\pm$ 0.4
P value	0.018*	0.018*	0.094	0.025*	0.100	0.852
rT(level A)						
Lower	1.2 $\pm$ 0.6	0.9 $\pm$ 0.3	2.4 $\pm$ 1.3	1.6 $\pm$ 0.7	2.1 $\pm$ 0.6	1.1 $\pm$ 0.3
Higher	1 $\pm$ 0.4	0.8 $\pm$ 0.3	2 $\pm$ 0.5	1.2 $\pm$ 0.7	1.5 $\pm$ 0.6	1 $\pm$ 0.3
P value	0.324	0.324	0.460	0.050	0.013	0.216
rBW						
Lower	1.2 $\pm$ 0.4	0.9 $\pm$ 0.3	2.4 $\pm$ 1	1.5 $\pm$ 0.5	1.8 $\pm$ 0.7	1.1 $\pm$ 0.3
Higher	1 $\pm$ 0.7	0.9 $\pm$ 0.4	2 $\pm$ 0.9	1.5 $\pm$ 0.9	1.9 $\pm$ 0.6	1 $\pm$ 0.2
P value	0.376	0.607	0.182	0.323	0.78	0.607

## Replanning

Replanning CT done at 40 Gy for all patients. Old plan applied to the replanning CT and difference in NTCP/TCP ratio calculated and correlation between the Body mass factors ,setup errors are analysed .

### CT SCAN OF THE PATIENT WITH OROPHARYNGEAL CANCER

SHOWING GOOD REGRESSION:



### NTCP AND TCP COMPARISION:

If the patient has large reduction ratio in circumference of ( $<1$ ) and thickness of ( $<0.94$ ) at the level of the mastoid tip on the 20th fraction of treatment and larger body weight or height and a performance score of 1-2.Replanning

has showed significant reduction in normal tissue complication probability when compared to patients who had no difference actual

NTCP	Patients with difference in BMFs and Setup errors	Patients without difference in BMFs and Setup errors
CORD (Mean %)	0.0000001909 %	0.0000026804%
BRAIN STEM(Mean %)	0.0000181882 %	0.0002341159%

### III) RESULTS AND ANALYSIS:

DIRECTION	MEAN DISPLACEMENT IN mm	POPULATION SYSTEMATIC ERROR IN mm	CTV-PTV MARGINS SUGGESTED
SUPEROINFERIOR	1.4	2.1	3.3
ANTEROPOSTERIOR	1.5	1	4.6
MEDIOLATERAL	2.1	1.5	6.5

COUCH ROTATION	POPULATION SYSTEMATIC ERROR	POPULATION RANDOM ERROR
DEGREES	0.30	0.34

**CORRELATION BETWEEN COUCH ROTATION AND ERRORS  
IN OTHER DIRECTIONS**

DIRECTION	SYSTEMATIC ERROR	RANDOM ERROR
ANTEROPOSTERIOR	NO CORRELATION	NO CORRELATION
SUPEROINFERIOR	NO CORRELATION	NO CORRELATION
MEDIOLATERAL	P=0.008	P=0.015

#CORRELATION BETWEEN THICKNESS AT LEVEL A AND BODY  
WEIGHT RATIO-NOT SIGNIFICANT(FROM CBCT AT 20 TH FRACTION)

**CORRELATION BETWEEN RATIO OF WEIGHT AND  
CIRCUMFERENCE AT 10 TH OR 20 TH FRACTION AT ALL THREE  
LEVELS.**

LEVELS	10 TH FRACTION	20 TH FRACTION
LEVEL A	NO CORRELATION	NO CORRELATION
LEVEL B	NO CORRELATION	NO CORRELATION
LEVEL C	NO CORRELATION	NO CORRELATION

## CORRELATION BETWEEN PRETREATMENT BMFs AND SETUP

### ERRORS:

FACTORS	AP-SE	AP-RE	SI- SE	SI-RE	ML- SE	ML- RE	CR-SE	CR-RE
LARGE WEIGHT	P=0.045*	NS	NS	P=0.023*	NS	NS	NS	NS
LONG HEIGHT	NS	NS	NS	P=0.002*	NS	NS	P=0.033*	P=0.067
PS 1 OR 2	P=0.042*	P=0.015*	NS	NS	NS	NS	NS	NS
AGE	NS	NS	NS	NS	NS	NS	NS	NS
BMI	NS	NS	NS	NS	NS	NS	NS	NS

### ASSOCIATION BETWEEN BMFs DURING RT(10<sup>TH</sup> FRACTION)

BMFs	AP-SE	AP-RE	ML-SE	ML-RE	SI-SE	SI-RE
THICKNESS LEVEL A	NS	NS	NS	P=0.043*	NS	NS
THICKNESS LEVEL B	NS	NS	NS	P=0.018*	NS	NS

### ASSOCIATION BETWEEN BMFs DURING RT(20<sup>TH</sup> FRACTION)

BMFs	AP-SE	AP-RE	ML-SE	ML-RE	SI-SE	SI-RE
rC	P=0.018*	P=0.018*	NS	NS	P=0.025*	NS
LEVEL A						
THICKNESS	NS	NS	P=0.013*	NS	NS	P=0.05*
LEVEL B						

### CORRELATION BETWEEN THICKNESS AT LEVEL A AND COUCH ROTATION(20<sup>TH</sup> FRACTION)

FRACTION	CR-SE	CR-RE
10 <sup>TH</sup>	NS	NS
20 <sup>TH</sup>	P=0.009*	P=0.019*

**\*-SIGNIFICANT**

**NS-NOT SIGNIFICANT.**

#At 10<sup>th</sup> fraction thickness at level C and ratio of Circumference at level A,B and C had no effect on setup errors.

#At 20<sup>th</sup> fraction, ratio of circumference at level B,C had thickness at level B,C had no significant correlation between errors.

#### **IV)DISCUSSION:**

Setup uncertainty may change dose distribution to target volume and OARs in head and neck cancers. To overcome this image guided radiotherapy and adaptive radiotherapy are used. According to the ICRU 62, inappropriate CTV-PTV margin leading to setup displacement and organ motion leads to underdose of CTV. To define this margin for Head and neck cancer, variability due to setup uncertainties must be corrected and organ motion may be neglected. But in practical scenario, extensive imaging for daily IGRT is not always feasible.

Based on these results patients with large body weight, height, and PS of 1 or above, can be selected for daily online imaging and adaptive radiotherapy.

CTV to PTV margins should be altered relevantly in all directions if IGRT is not possible. Head and Neck cancer patients receiving RT exhibit significant anatomical changes due to tumor regression after the delivery of therapeutic dose.

The geometric change of the target and OARs should be assessed with the help of on-line images acquired during the treatment regimen. Patients having unfit



immobilizations are usually considered for ART. But the correct guidelines for adaptive radiotherapy are still lacking. Albeit the increase in the quality of life of the patients undergoing ART, it also increases the workload of the staff and the cost of the treatment to the patients. This study was done mainly to determine the effect of Body mass factors before and during radiation on positioning displacement for patients treated with Head and neck cancers and to correlate between Body Mass Factors and the extent of daily setup errors. These results helps us to ascertain who should be regarded for on-line image guided radiotherapy before starting RT, and determine those who really require ART to decrease setup error.

## **V) CONCLUSION:**

Head and neck cancer patients with large body weight or height, and performance status score of 1–2 receiving radiation either with or without chemotherapy are recommended to be done daily online imaging. Patients exhibiting a large reduction ratio in circumference ( $<1$ ) and thickness ( $<0.94$ ) on the 20<sup>th</sup> fraction of the treatment at the level of the mastoid tip can be considered for Adaptive planning.

## **VI)REFERENCES:**

1. Eisbruch A, Foote RL, O'Sullivan B, Beitler JJ, Vikram B: Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. *Semin Radiat Oncol* 2002, 12:238–249.
2. Li H, Zhu XR, Zhang L, Dong L, Tung S, Ahamad A, Chao KS, Morrison WH, Rosenthal DI, Schwartz DL, et al: Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. *Int J Radiat Oncol Biol Phys* 2008, 71:916–925.
3. Stock M, Palm A, Altendorfer A, Steiner E, Georg D: IGRT induced dose burden for a variety of imaging protocols at two different anatomical sites. *Radiother Oncol* 2012, 102:355–363.
4. Yu Y, Michaud AL, Sreeraman R, Liu T, Purdy JA, Chen AM: Comparison of daily versus nondaily image-guided radiotherapy protocols for patients treated with intensity-modulated radiotherapy for head and neck cancer. *Head & neck* 2013. doi:10.1002/hed.23401 [Epub ahead of print].

5. Castadot P, Lee JA, Geets X, Gregoire V: Adaptive radiotherapy of head and neck cancer. *Semin Radiat Oncol* 2010, 20:84–93.
- 6.. Gregoire V, Coche E, Cosnard G, Hamoir M, Reyhler H: Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. *Radiother Oncol* 2000, 56:135–150.
7. Remeijer P, Geerlof E, Ploeger L, Gilhuijs K, van Herk M, Lebesque JV: 3-D portal image analysis in clinical practice: an evaluation of 2-D and 3-D analysis techniques as applied to 30 prostate cancer patients. *Int J Radiat Oncol Biol Phys* 2000, 46:1281–1290.
8. De Neve W, Van den Heuvel F, De Beukeleer M, Coghe M, Thon L, De Roover P, Van Lancker M, Storme G: Routine clinical on-line portal imaging followed by immediate field adjustment using a tele-controlled patient couch. *Radiother Oncol* 1992, 24:45–54.

9. Duma MN, Kampfer S, Schuster T, Aswathanarayana N, Fromm LS, Molls M, Andratschke N, Geinitz H: Do we need daily image-guided radiotherapy by megavoltage computed tomography in head and neck helical tomotherapy. The actual delivered dose to the spinal cord. *Int J Radiat Oncol Biol Phys* 2012, 84:283–288.
10. Mongioj V, Orlandi E, Palazzi M, Deponti E, Marzia F, Stucchi C, Sangalli C, Fallai C, Zonca G, Olmi P, Pignoli E: Set-up errors analyses in IMRT treatments for nasopharyngeal carcinoma to evaluate time trends, PTV and PRV margins. *Acta Oncol* 2011, 50:61–71.
11. Pehlivan B, Pichenot C, Castaing M, Auperin A, Lefkopoulos D, Arriagada R, Bourhis J: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. *Acta Oncol* 2009, 48:440–445.
12. Samuelsson A, Mercke C, Johansson KA: Systematic set-up errors for IMRT in the head and neck region: effect on dose distribution. *Radiother Oncol* 2003, 66:303–311.

13. van Lin EN, van der Vicht L, Huizenga H, Kaanders JH, Visser AG: Set-up improvement in head and neck radiotherapy using a 3D off-line EPID based correction protocol and a customised head and neck support. *Radiother Oncol* 2003, 68:137–148.

14. Bujold A, Craig T, Jaffray D, Dawson LA: Image-guided radiotherapy: has it influenced patient outcomes? *Semin Radiat Oncol* 2012, 22:50–61.

15. ICRU: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). In *ICRU Report. Volume 62*. Bethesda: International Commission on Radiation Units and Measurements; 1999.

16. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, et al: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* 2011, 377:557–567.

17. Schwartz DL, Garden AS, Shah SJ, Chronowski G, Sejpal S, Rosenthal DI, Chen Y, Zhang Y, Zhang L, Wong PF, et al: Adaptive radiotherapy for head and neck cancer—dosimetric results from a prospective clinical trial. *Radiother Oncol* 2013, 106:80–84.

18. Yang H, Hu W, Wang W, Chen P, Ding W, Luo W: Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2013,85:e47–e54.

19. Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S: The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. *Radiother Oncol* 2011, 98:23–27.

20. McDermott LN, Wendling M, Sonke JJ, van Herk M, Mijnheer BJ: Anatomy changes in radiotherapy detected using portal imaging. *Radiother Oncol* 2006, 79:211–217.

21. Dobs HJ, Greener T, Driver D. Geometric uncertainties in radiotherapy of the breast. In *Imaging for Target Volume Determination in Radiotherapy*. Proceedings of ESTRO Course; 2004 April 18-22; Munich, Germany, 2004. p. 313-41.

22. Stroom JC, Heijmen BJM. Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. *Radiother Oncol* 2002;64:75-83.

23. Jaffray DA, Siewersden JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. *Int J Radiat Oncol Biol Phys* 2002;53:1337-49.

24. de Boer JCJ, Heijmen BJM, Pasma KL, Visser AG. Characterisation of a high elbow, fluoroscopic electronic portal imaging device for portal dosimetry. *Phys Med Biol* 2000;45:197-216.

25. International Commission on Radiation Units and Measurements. ICRU report 62: Prescribing, recording, and reporting photon beam therapy. Bethesda: ICRU Publications; 1999.

26. Strom JC, de Boer JCJ, Huizenga H, Visser AG. Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. *Int J Radiat Oncol Biol Phys* 1999;43:905-19.

27. Herman MG, Balter J, Jaffray D, et al. Clinical use of electronic portal imaging: Report of AAPM Radiation Therapy Committee Task group 58. Med Phys 2001;28:712-37.

28. van Lin ENJ, van der Vicht L, Huizenga H, Kaanders J, Viser AG. Set-up improvement in head and neck radiotherapy using 3D off-line EPID-based correction protocol and a customized head and neck support. Radiother Oncol 2003;68:137-48.

29. Pluim JP, Maintz JB, Viergever MA (2003) Mutual-information based registration of medical images: a survey. IEEE Trans Med Imaging 22:986–1004

30. Hill DL, Batchelor PG, Holden M, Hawkes DJ (2001) Medical image registration. Phys Med Biol 46:R1–R45

31. Schad LR, Boesecke R, Schlegel W, Hartmann GH, Sturm V, Strauss LG, Lorenz WJ (1987) Three dimensional image correlation of CT, MR, and PET studies in radiotherapy treatment planning of brain tumors. J Comput Assist Tomogr 11:948–954



32. Hemler PF, Napel S, Sumanaweera TS, Pichumani R, van den Elsen PA, Martin D, Drace J, Adler JR, Perkash I (1995) Registration error quantification of a surface-based multimodality image fusion system. *Med Phys* 22:1049–1056
33. Kessler ML, Pitluck S, Petti P, Castro JR (1991) Integration of multimodality imaging data for radiotherapy treatment planning. *Int J Radiat Oncol Biol Phys* 21:1653–1667
34. Rosenman JG, Miller EP, Tracton G, Cullip TJ (1998) Image registration: an essential part of radiation therapy treatment planning. *Int J Radiat Oncol Biol Phys* 40:197–205
35. Yan CH, Whalen RT, Beaupre GS, Sumanaweera TS, Yen SY, Napel S (1998) A new frame-based registration algorithm. *Med Phys* 25:121–128
36. Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT (1989) Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. *J Comput Assist Tomogr* 13:20–26

37. Brunie L, Lavallee S, Troccaz J, Cinquin P, Bolla M (1993) Preand intra-irradiation multimodal image registration: principlesand first experiments.

Radiother Oncol 29:244–252

19:117–124

38. Yan D, Wong JW, Vicini F, Michalski J, Pan C, Frazier A, Horwitz E, Martinez A (1997) Adaptive modification of treatment planning to minimize the deleterious effects of treatment setuperrors. Int J Radiat Oncol Biol Phys 38:197–

206

39. Court L, Rosen I, Mohan R, Dong L (2003) Evaluation of mechanical precision and alignment uncertainties for an integrated CT/LINAC system. Med Phys

30:1198–1210

40. Yan D, Jaffray DA, Wong JW (1999) A model to accumulate fractionated dose in a deforming organ. Int J Radiat Oncol Biol Phys 44:665–675